Michel Delforge, MD, PhD, University of Leuven, Leuven, Belgium, discusses the future of chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma and outlines his highlights from ASH 2020. In the longer term, Dr Delforge believes that CAR T-cell therapy will be used in earlier settings and in higher-risk subgroups of multiple myeloma patients. In the shorter-term, he highlights research aiming to achieve longer persistence of CAR T-cells, the development of new manufacturing technologies, and the possibility of dual-targeting and allogeneic CAR T-cell therapies. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.